First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0

作者：

Cohen, Yael C.

Morillo, Daniel

Gatt, Moshe E.

Sebag, Michael

Kim, Kihyun

Min, Chang-Ki

Oriol, Albert

Ocio, Enrique M.

Yoon, Sung-Soo

Mateos, Maria-Victoria

Chu, Michael

Rodriguez-Otero, Paula

Avivi, Irit

Guo, Yue

Krevvata, Maria

Peterson, Michelle R.

Beelen, Melissa Jo

Vanak, Jill

Banerjee, Arnob

Magen, Hila

机构：

[1] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[3] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[4] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel

[5] McGill Univ, Montreal, PQ, Canada

[6] MUHC, Montreal, PQ, Canada

[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[8] Seoul St Marys Hosp, Seoul, South Korea

[9] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[10] Marques Valdecilla Univ Hosp, Santander, Spain

[11] Seoul Natl Univ, Coll Med, Seoul, South Korea

[12] Univ Hosp Salamanca, Salamanca, Spain

[13] Alberta Hlth Serv, Edmonton, AB, Canada

[14] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[15] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[16] Janssen Res & Dev, Spring House, PA USA

[17] Tel Aviv Univ, Chaim Sheba Med Ctr, Sackler Fac Med, Ramat Gan, Israel

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8002

引用

页数：1